




11W 1649

AMENDMENT TRANSMITTAL LETTER				Docket No. 102728-P01-004	
Application No. 09/880,097		Filing Date June 14, 2001		Examiner D. Kolker	
				Art Unit 1649	
Applicant(s): Anton Wellstein					
Invention: PLEIOTROPHIN GROWTH FACTOR RECEPTOR FOR THE TREATMENT OF PROLIFERATIVE, VASCULAR AND NEUROLOGICAL DISORDERS					
TO THE COMMISSIONER FOR PATENTS					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	26	- 68 =	0	x 25.00	0
Independent Claims	4	- 9 =	0	x 100.00	0
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0
<input checked="" type="checkbox"/> Large Entity <input type="checkbox"/> Small Entity					
<input checked="" type="checkbox"/> No additional fee is required for this amendment.					
<input checked="" type="checkbox"/> Please charge Deposit Account No. <u>18-1945</u> in the amount of \$ <u>0.00</u> . A duplicate copy of this sheet is enclosed.					
<input type="checkbox"/> A check in the amount of \$ _____ to cover the filing fee is enclosed.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>18-1945</u> as described below. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> Credit any overpayment.					
<input checked="" type="checkbox"/> Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.					
<u>Anita Varma</u> Anita Varma Attorney/Agent Reg. No.: 43,221 FISH & NEAVE IP GROUP, ROPES & GRAY LLP One International Place Boston, Massachusetts 02110-2624 (617) 951-7796				Dated: <u>January 24, 2007</u>	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.					
Dated: <u>1-24-06</u> Signature: <u>Maura A. Gallagher</u> (Maura A. Gallagher)					



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 1-24-07

Signature: Maura A. Gallagher
(Maura A. Gallagher)

Docket No.: 102728-P01-004
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Anton Wellstein

Application No.: 09/880097

Confirmation No.: 3830

Filed: June 14, 2001

Art Unit: 1649

For: PLEIOTROPHIN GROWTH FACTOR
RECEPTOR FOR THE TREATMENT OF
PROLIFERATIVE, VASCULAR AND
NEUROLOGICAL DISORDERS

Examiner: Kolker, Daniel E.

AMENDMENT AND RESPONSE TO OFFICE ACTION UNDER 37 CFR 1.111

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Amendment is being filed in response to the Office Action dated October 24, 2006 in the above-identified application. Please amend the above-identified U.S. patent application as follows:

Amendments to the claims begin on page 2 of this paper.

Remarks begin on page 5 of this paper.